Infinity's horizons broaden with rich AbbVie co-development deal
This article was originally published in Scrip
Infinity Pharmaceuticals will expand its capacity for single-agent and combination therapy oncology studies for duvelisib (IPI-145), and improve its ability to pay future milestone and royalty fees under prior agreements, through an $805m partnership with AbbVie.
You may also be interested in...
Infinity's hopes for accelerated approval of duvelisib based on the DYNAMO study have been dashed, so as the company plots a new strategy for the PI3K inhibitor – with or without its partner AbbVie – it has cut discovery research operations, including 46 jobs.
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.